These results suggested that the combination of EGFR and CXCR4 may be an effective method to monitor and predict prognostics of NSCLC patients after surgery, and it may provide information to suggest tumor recurrence much earlier than the routine clinical evaluation. Here, CXCR4 is linked to non-small cell lung carcinoma.